TBD

TBD

TBD

TBD

TBD

TBD

Vicki was diagnosed with Young Onset Parkinson's Disease (YOPD) in February 2007, aged just 35. She lives in the North East of England with her partner Ken and has two grown up sons.  She blogs full time about living with Parkinson's and is an advocate for better treatment with a view to a cure. Vicki is passionate about speaking about living with Parkinson's and has travelled the word telling her powerful, sad, funny, disturbing, medical-history-making and ultimately heart warming story in her own unique style. Life with Parkinson's is never boring and Vicki's aim is to educate and inspire you - with some laughter, tears and brain surgery along the way.   

Filippo Petti was appointed Chief Executive Officer of Leucid Bio in July 2023. Prior to joining Leucid, Mr. Petti was CEO, CFO and Executive Director of Celyad Oncology SA, a biotech company focused on cell therapies for cancer. Prior to Celyad Oncology SA, Mr. Petti spent several years as a healthcare investment banker at Wells Fargo Securities and William Blair & Company, where he specialised in working with cell & gene therapy companies. In addition, Mr. Petti has worked in equity research covering U.S. biotechnology companies both at William Blair & Company and Wedbush Securities. He began his career as a research scientist at OSI Pharmaceuticals, Inc. focused on drug discovery and translational research, before transitioning to corporate development with the company. Mr. Petti holds a Master of Business Administration from Cornell University, a Master of Science from St. John’s University and a dual Bachelor of Science from Syracuse University.

Stephen C. Rocamboli is a seasoned life sciences executive with a long track record in building and scaling innovative biotechnology companies. With a focus on development stage immuno-oncology, he drives corporate strategy and leads executive teams in the development and advancement of novel immunotherapies.  He holds a B.A. from The State University of New York at Albany and a J.D. from Fordham University School of Law.

Dr. David Cohan brings more than eight years of biopharmaceutical industry experience to his role, following a tenure-track faculty position in surgical oncology at Roswell Park Cancer Institute–SUNY Buffalo. At Amgen and other organizations, he has held leadership roles spanning clinical development, medical affairs, and business development, with a focus on therapeutic modalities such as monoclonal antibodies, bispecifics, antibody-drug conjugates (ADCs), oncolytic viruses, cytokine analogs, and small molecules.

He has driven clinical and regulatory strategy from first-in-human studies through pivotal Phase 3 trials, contributing to protocol development and authoring key study documents. Dr. Cohan has led multiple ODAC preparations, reimbursement submissions, and an ICER defense. Board certified in general surgery and fellowship trained in head and neck surgical oncology and plastic and reconstructive surgery, he is also an expert in surgical critical care, melanoma, wound healing, and tumor immunology. His academic contributions include over 40 peer-reviewed publications and ongoing service as a peer reviewer for a leading oncology journal.

Dr. Cohan holds dual BAs in Slavic Languages and Literatures and English Literature from Yale University and earned his MD from Stanford University. He is an elected fellow of the American College of Surgeons, the Society of Surgical Oncology, and the American Head & Neck Society.